Lipoprotein (a) measurements for clinical application
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific antibodies directed to apo(a) more difficult and poses significant challenges to the development of immunoassays to measure its concentration in plasma or serum samples. Apo(a) is extremely variable in size not only between but also within individuals because of the presence of two different, genetically determined apo(a) isoform sizes. Therefore, the antigenic determinants per particle available to interact with the antibodies will vary in the samples and the calibrators, thus contributing to apo(a) size-dependent inaccuracy of different methods. The lack of rigorous validation of the immunoassays and common means of expressing Lp(a) concentrations hinder the harmonization of results obtained by different studies and contribute to the lack of common cut points for identification of individuals at risk for coronary artery disease or for interventions aimed at reducing Lp(a) levels. The aim of our review is to present and critically evaluate the issues surrounding the measurements of Lp(a), their impact on the clinical interpretation of the data, and the obstacles we need to overcome to achieve the standardization of Lp(a) measurements.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note that direct LDL-C measurements also have limitations, including systematic bias and inaccuracy in patients with dyslipidaemia, especially for high TG levels [88-90].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [90]
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Available methods are, to a varying degree, influenced by the Apo(a) isoform.(91) Furthermore, the concentration of Lp(a) is reported as either a molar concentration (nmol/L) or as a mass (mg/ dL) by the various assays, and conversion between molar and mass concentrations has been found to be both size- and concentrat…”
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“This topic was recently reviewed by Marcovina and Albers (40), which provided full details of assay methodologies and limitations.”
BackgroundInfluentialLipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citationPatel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
“An extensive review of the numerous issues affecting the measurement of Lp(a) has been published recently (40).”
BackgroundSelf-citationA focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.03.001 · Cited by 328
“37 Therefore, antibodies that recognize epitopes in the KIV2 sequence tend to underestimate the concentrations of smaller Lp(a) isoform sizes (which tend to be associated with higher Lp(a) levels and higher ASCVD risk), while overestimating those of larger isoforms.”
BackgroundOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0153-2 · Cited by 284
Lipoprotein(a) and Cardiovascular Disease
Kamstrup, P. R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa247 · Cited by 256
HEART UK consensus statement on Lipoprotein(a): A call to action
Cegla, J., Neely, R. D. G., France, M., Ferns, G., Byrne, C. D., Halcox, J., Datta, D., Capps, N., Shoulders, C., Qureshi, N., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.011 · Cited by 247
“Although there remain large differences between assays, these protocols have reduced the bias caused by isoform size of Lp(a) and have made within study comparisons more robust [15].”
BackgroundMethodInfluentialRoeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307983 · Cited by 227
“These are all translated and lead to a size polymorphism of apo(a), which is causally associated with Lp(a) concentrations in an inverse manner.(4,5) Lp(a) isoforms have been categorized as small (≤22 KIV repeats) or large (>22 KIV repeats) with small isoforms, implying an ≈2-fold higher risk of CVD.”
BackgroundLipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Gudbjartsson, D. F., Thorgeirsson, G., Sulem, P., Helgadottir, A., Gylfason, A., Saemundsdottir, J., Bjornsson, E., Norddahl, G. L., Jonasdottir, A., Jonasdottir, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.019 · Cited by 226
“The measurement of Lp(a) molar concentration is not standardized in clinical practice; therefore, absolute thresholds and effect estimates may depend on the measurement platform (15).”
BackgroundNewman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
Lampsas, S., Xenou, M., Oikonomou, E., Pantelidis, P., Lysandrou, A., Sarantos, S., Goliopoulou, A., Kalogeras, K., Tsigkou, V., Kalpis, A., et al. (2023) · Molecules · doi:10.3390/molecules28030969 · Cited by 162
“Moreover, there are diagnostic obstacles in the field since standardized Lp(a) measurement methods are lacking [12,13].”
Jawi, M., Frohlich, J. J., & Chan, S. (2020) · Journal of Lipids · doi:10.1155/2020/3491764 · Cited by 207
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 186
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
Tsimikas, S., & Marcovina, S. M. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.019 · Cited by 176
Self-citationSahebkar, A., Reiner, Ž., Simental‐Mendía, L. E., Ferretti, G., & Cicero, A. F. G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.007 · Cited by 157
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Nissen, S. E., Wolski, K., Cho, L., Nicholls, S. J., Kastelein, J. J. P., Leitersdorf, E., Landmesser, U., Blaha, M. J., Lincoff, A. M., Morishita, R., et al. (2022) · Open Heart · doi:10.1136/openhrt-2022-002060 · Cited by 165
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies
Orsó, E., & Schmitz, G. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0084-1 · Cited by 125
“Apo(a) shows a high amino acid sequence homology to the serine protease plasminogen, and consists of a carboxy-terminal, enzymatically inactive, protease-like domain followed by a kringle-V domain and a variable kringle-IV (K-IV) domain ([5] and references therein).”
InfluentialLipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
Arsenault, B. J., & Kamstrup, P. R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.015 · Cited by 132
Enas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.03.004 · Cited by 135
Vuorio, A. F., Watts, G. F., Schneider, W. J., Tsimikas, S., & Kovanen, P. T. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12981 · Cited by 127
Lp(a): When and how to measure it
Cegla, J., France, M. W., Marcovina, S. M., & Neely, R. D. G. (2020) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563220968473 · Cited by 123
Self-citationScharnagl, H., Stojakovic, T., Dieplinger, B., Dieplinger, H., Erhart, G., Kostner, G. M., Herrmann, M., März, W., & Grammer, T. B. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.015 · Cited by 114
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Greco, A., Finocchiaro, S., Spagnolo, M., Faro, D. C., Mauro, M. S., Raffo, C., Sangiorgio, G., Imbesi, A., Laudani, C., Mazzone, P. M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.069210 · Cited by 141
“43 The lack of global standardization in existing assays introduces a potential source of bias in Lp(a) measurement, with results reported either in milligrams per deciliter or nanomoles per liter, and conversion from one to another strongly discouraged.”
Lipoprotein(a) catabolism: a case of multiple receptors
McCormick, S. P. A., & Schneider, W. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.003 · Cited by 107
Vinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 139
“At present it is well known that, with this method, Lp(a) concentrations are overestimated in patient samples containing large isoforms and underestimated in samples containing small isoforms; however, recent methods that use five independent calibrators with a large range of Lp(a) levels and distribution of apo(a) is…”
Tsimikas, S., Fazio, S., Viney, N. J., Xia, S., Witztum, J. L., & Marcovina, S. M. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.07.003 · Cited by 109
Self-citationRepeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk
Trinder, M., Paruchuri, K., Haidermota, S., Bernardo, R., Zekavat, S. M., Gilliland, T., Januzzi, J., & Natarajan, P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.055 · Cited by 102
Welsh, P., Welsh, C., Celis-Morales, C. A., Brown, R., Ho, F. K., Ferguson, L. D., Mark, P. B., Lewsey, J., Gray, S. R., Lyall, D. M., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa063 · Cited by 98
“The ethnicity-specific centiles we report confirm and extend observations in other cohorts, most noticeably higher Lp(a) in black people.(30) We would expect a higher PAF for CVD outcomes in black”
Arnold, M., Schweizer, J., Nakas, C. T., Schütz, V., Westphal, L. P., Inauen, C., Pokorny, T., Luft, A. R., Leichtle, A. B., Arnold, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab081 · Cited by 108
de Boer, L. M., Hof, M. H. P., Wiegman, A., Stroobants, A. K., Kastelein, J. J. P., & Hutten, B. A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.004 · Cited by 110
Thomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309549 · Cited by 96
Self-citationInterleukin-6 in atherosclerosis: atherogenic or atheroprotective?
Reiss, A. B., Siegart, N. M., & Leon, J. D. (2017) · Clinical Lipidology · doi:10.1080/17584299.2017.1319787 · Cited by 124
Lipoprotein(a): A missing culprit in the management of athero‐thrombosis?
Ferretti, G., Bacchetti, T., Johnston, T. P., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26050 · Cited by 98
“Marcovina and Albers (2016) have developed a Lp(a) assay that was independent of the apo(a) isoforms and characterized a different metric (particle concentration (Lp(a)-”
BackgroundLiu, H., Cao, Y., Jin, J., Zhang, H., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Xu, R., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014581 · Cited by 88
“Furthermore, for routine clinical care, currently available assays linked to the World Health Organization/International Federation of Clinical Chemistry and Laboratory Medicine standard are able to detect high-risk patients with acceptable accuracy.(15,50) Fourth, recall bias in the clinics and with telephone calls i…”
MethodLipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 102
“There are several assays available [10], which are, to varying degrees, influenced by the apo(a) isoform [11].”
BackgroundWilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 97
“On the other hand, other studies have shown that Lp(a) clearly contributes to residual risk in statin-treated subjects.(43,54,55) In a 2018 meta-analysis, elevated Lp(a) was a stronger risk factor than LDL-C for incident CVD in statin-treated than in placebo-treated subjects.”
BackgroundMethodResultInfluentialLipoprotein(a): Knowns, unknowns and uncertainties
Ruscica, M., Sirtori, C. R., Corsini, A., Watts, G. F., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105812 · Cited by 96
Saeed, A., Sun, W., Agarwala, A., Virani, S. S., Nambi, V., Coresh, J., Selvin, E., Boerwinkle, E., Jones, P. H., Ballantyne, C. M., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.022 · Cited by 94
“, Tokyo, Japan) insensitive to apo(a) isoform variations (10).”
BackgroundLipoprotein (a): a historical appraisal
Kostner, K. M., & Kostner, G. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r071571 · Cited by 82
Marcovina, S. M., Clouet-Foraison, N., Koschinsky, M. L., Lowenthal, M. S., Orquillas, A., Boffa, M. B., Hoofnagle, A. N., & Vaisar, T. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa324 · Cited by 72
“With the renewed interest in Lp(a) as a causal risk factor for cardiovascular disease, poor method accuracy and lack of method standardization are the major obstacles for the clinical implementation of Lp(a) measurements (5, 10, 16, 36).”
BackgroundMethodSelf-citationGolledge, J., Rowbotham, S. E., Velu, R., Quigley, F., Jenkins, J. S., Bourke, M., Bourke, B. M., Thanigaimani, S., Chan, D. C., & Watts, G. F. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015355 · Cited by 67
Viney, N. J., Yeang, C., Yang, X., Xia, S., Witztum, J. L., & Tsimikas, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.014 · Cited by 70
Solnica, B., Sygitowicz, G., Sitkiewicz, D., Cybulska, B., Jozwiak, J. J., Odrowąż‐Sypniewska, G., & Banach, M. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.93253 · Cited by 71
“This genetically determined size of the Lp(a) particle is inversely proportional to the rate of its synthesis mainly in the liver and the serum/plasma concentration – particles of a lower mass (lower number of KIV-2 repeats) are present in a higher concentration while particles of a higher mass (high number of KIV-2 r…”
BackgroundMarcovina, S. M., Viney, N. J., Hughes, S. G., Xia, S., Witztum, J. L., & Tsimikas, S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.024 · Cited by 69
Self-citationLipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target
Fusco, S. A. D., Arca, M., Scicchitano, P., Alonzo, A., Perone, F., Gulizia, M. M., Gabrielli, D., Oliva, F. G., Imperoli, G., & Colivicchi, F. (2022) · Heart · doi:10.1136/heartjnl-2021-320708 · Cited by 71
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
Tasdighi, E., Adhikari, R., Almaadawy, O., Leucker, T. M., & Blaha, M. J. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031023-100609 · Cited by 72
Szarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066398 · Cited by 65
“8,21 Bilevel native serum internal quality control samples were measured in triplicate and evaluated by Levey-Jennings plots with adjusted Westgard rules to fit a multiplex test to assess assay performance.”
MethodNandakumar, R., Matveyenko, A., Thomas, T., Pavlyha, M., Ngai, C., Holleran, S., Ramakrishnan, R., Ginsberg, H. N., Karmally, W., Marcovina, S. M., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p082834 · Cited by 58
“It has been demonstrated that Lp(a) contains one molecule of apo(a) per particle, and therefore the values in nmol/l indicate the number of Lp(a) particles per liter (22, 23).”
BackgroundSelf-citationSwerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 62
“particle concentration-based reporting in nmol/L) has been increasingly advocated since these account adequately for isoform size, mitigating against underestimating levels of small Lp(a) isoforms or overestimating of large Lp(a) isoforms.(20,21) Lp(a) has physiological and pathological roles.”
BackgroundLipoprotein (a), Inflammation, and Atherosclerosis
Fusco, S. A. D., Maggioni, A. P., Scicchitano, P., Zuin, M., D’Elia, E., & Colivicchi, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072529 · Cited by 68
“The Marcovina assay, which uses monoclonal antibodies, is the least apo(a)-size-sensitive immunoassay currently available on the market [34].”
MethodLipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations
Shah, N. P., Pajidipati, N. J., McGarrah, R. W., Návar, A. M., Vemulapalli, S., Blazing, M. A., Shah, S. H., Hernandez, A. F., & Patel, M. R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.043 · Cited by 65
Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns
Erhart, G., Lamina, C., Lehtimäki, T. J., Marques-Vidal, P. M., Kähönen, M. A. P., Vollenweider, P., Raitakari, O. T., Waeber, G., Thorand, B., Strauch, K., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310865 · Cited by 61
Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
Clarke, R., Ende, A. V., Schmidt, L. E., Yin, X., Hill, M., Hughes, A. D., Pechlaner, R., Willeit, J., Kiechl, S. J., Watkins, H. C., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321690 · Cited by 53
New Frontiers in Lp(a)-Targeted Therapies
Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 57
Obisesan, O. H., Kou, M., Wang, F. M., Boakye, E., Honda, Y., Uddin, S. M. I., Dzaye, O. D. A., Osei, A. D., Orimoloye, O. A., Howard, C. M., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024870 · Cited by 56
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
Boffa, M. B., Stranges, S., Klar, N., Moriarty, P. M., Watts, G. F., & Koschinsky, M. L. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.08.012 · Cited by 51
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Kamstrup, P. R., Neely, R. D. G., Nissen, S. E., Landmesser, U., Haghikia, A., Costa‐Scharplatz, M., Abbas, C. A., & Nordestgaard, B. G. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae032 · Cited by 54
Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes
Kelsey, M. D., Mulder, H. S., Chiswell, K., Lampron, Z. M., Nilles, E. K., Kulinski, J. P., Joshi, P. H., Jones, W. S., Chamberlain, A. M., Leucker, T. M., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100478 · Cited by 50
Marcovina, S. M., Navabi, N., Allen, S., Gonen, A., Witztum, J. L., & Tsimikas, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100239 · Cited by 53
“In contrast, less immunocomplexes are formed with smaller isoforms, which are generally found in subjects with high plasma Lp(a), and thus, the high values tend to be underestimated (3, 8).”
BackgroundMethodInfluentialSelf-citationDiederiks, N. M., van der Burgt, Y. E. M., Ruhaak, L. R., & Cobbaert, C. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2199353 · Cited by 45
“…selected to mimic the relation between KIV 2 repeats and Lp(a) concentration in patient specimens, in order not to underestimate the association between Lp(a) and CVD [6] Alternative calibration strategies for immunoassays could be based on either recombinant protein or native serum samples.”
BackgroundMethodInfluentialde Boer, L. M., Wiegman, A., Kroon, J., Tsimikas, S., Yeang, C., Peletier, M. C., Revers, A., Kastelein, J. J. P., Zwinderman, A. H., & Hutten, B. A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00156-0 · Cited by 46
Littmann, K., Wodaje, T., Alvarsson, M., Bottai, M., Eriksson, M., Parini, P., & Brinck, J. W. (2019) · Diabetes Care · doi:10.2337/dc19-1398 · Cited by 43
“Hence, comparison of results from studies using different methods for Lp(a) measurement is problematic, and the use of standardized methods, traceable to an international reference material, are desirable (7).”
ResultQuantifying apolipoprotein(a) in the era of proteoforms and precision medicine
Ruhaak, L. R., & Cobbaert, C. M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.10.010 · Cited by 44
Virani, S. S., Koschinsky, M. L., Maher, L. V., Mehta, A., Orringer, C. E., Santos, R. D., Shapiro, M. D., & Saseen, J. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.01.002 · Cited by 46
“This has hindered comparison of data from studies using different methods of Lp (a)measurement and created uncertainty for clinicians regarding interpretation of clinical Lp(a) measurements.(8) As such, reliable methodologies for measuring Lp(a) that address both standardization and harmonization are needed.”
MethodEfficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
Karwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hurh, E., Hoenlinger, A., Margolskee, A., Xia, S., & Tsimikas, S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.12.001 · Cited by 44
Chieng, D., Pang, J., Ellis, K. L., Hillis, G. S., Watts, G. F., & Schultz, C. J. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.090 · Cited by 42
Catapano, A. L., Daccord, M., Damato, E., Humphries, S. E., Neely, R. D. G., Nordestgaard, B. G., Pistollato, M., & Steinhagen‐Thiessen, E. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.02.013 · Cited by 42
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Ljungberg, J., Holmgren, A., Bergdahl, I. A., Hultdin, J., Norberg, M., Näslund, U., Johansson, B. H., & Söderberg, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007160 · Cited by 40
“In contrast, previous studies typically determined the mass concentration (mg/dL) of plasma Lp(a) levels.(44) That method does not measure the different Lp(a) isoforms equally, and thus, the measurements are not traceable to international standards.”
ResultWu, M., Xu, K., Guo, Y., Yu, J., Wu, Y., & Lin, L. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06906-9 · Cited by 40
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Loh, W. J., Chang, X., Aw, T. C., Phua, S. K., Low, A. F.-H., Chan, M. Y., Watts, G. F., & Heng, C. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.018 · Cited by 38
The re-emergence of lipoprotein(a) in a broader clinical arena
Tsimikas, S. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.005 · Cited by 38
Lipoprotein (a): Recent Updates on a Unique Lipoprotein
Saeed, A., Kinoush, S., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00940-5 · Cited by 35
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 43
“Use assays expressing (LOE B/Class I) [49] In the absence of Lp(a) standardization, use a 5-point calibration against the reference (LOE B/Class I) [49] Do not use a single (LOE C/Class III) [49,186] ≈ ≥”
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 46
The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta‐analysis
Jamialahmadi, T., Reiner, Ž., Alidadi, M., Kroh, M., Almahmeed, W. A., Ruscica, M., Sirtori, C. R., Rizzo, M., Santos, R. D., & Sahebkar, A. (2022) · BioMed Research International · doi:10.1155/2022/8435133 · Cited by 37
“Indeed, because of the structural properties of Lp(a), none of the available commercial assays for Lp(a) quantification is 100% inherently isoform-sensitive [81].”
Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate
Kostner, K., Kostner, G. M., & Wierzbicki, A. S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.032 · Cited by 36
Lipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 35
Virani, S. S. (2017) · Frontiers in bioscience · doi:10.2741/4635 · Cited by 38
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science
Scipione, C. A., Koschinsky, M. L., & Boffa, M. B. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1415866 · Cited by 36
“This assay uses a five-point calibration system, can be traced to the WHO/IFCC reference material, and expresses Lp(a) concentration in nanomoles per liter with minimal apo(a) isoform size bias [34].”
MethodElevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Handhle, A., Viljoen, A., & Wierzbicki, A. S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266244 · Cited by 33
Pro(a)LiFe-Study Group, Klingel, R., Heibges, A., & Fassbender, C. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0082-3 · Cited by 32
Enkhmaa, B., Anuurad, E., Zhang, W., Yue, K., Li, C.-S., & Berglund, L. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078212 · Cited by 30
“be affected by apo(a) sizes (41), necessitating confirma-”
BackgroundShiyovich, A., Berman, A. N., Besser, S. A., Biery, D. W., Kaur, G., Divakaran, S., Singh, A., Huck, D. M., Weber, B., Plutzky, J., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034493 · Cited by 31
“36 All Lp(a) laboratory testing was performed at commercial laboratories over the study period using industry-standard assays.”
MethodRole of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals
Patel, D., Koschinsky, M. L., Agarwala, A., Natarajan, P., Bhatia, H. S., Mehta, A., Patel, J., Peters, M. G., Pandya, S., Sagheer, U., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040361 · Cited by 35
“114 The European Atherosclerosis Society explicitly recommends using isoform-insensitive assays reported in molar units (nmol/L) for Lp(a) measurement to enhance clinical reliability.”
Lipoprotein(a): new insights from modern genomics
Afshar, M. S., & Thanassoulis, G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000392 · Cited by 30
Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome
Jubran, A., Zetser, A., & Zafrir, B. (2019) · Cardiology Journal · doi:10.5603/cj.a2018.0106 · Cited by 32
“Nevertheless, despite these associations, the value of Lp(a) as a prognostic biomarker remains controversial and is incompletely defined due to lack of standardized assays [12], the limited therapeutic options for significantly lowering Lp(a) and the need of outcome data showing the benefit of lowering Lp(a) levels [1…”
BackgroundHohenstein, B., Julius, U., Lansberg, P. J., Jaeger, B. R., Mellwig, K., Weiss, N., Graehlert, X., Roeder, I., & Ramlow, W. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.009 · Cited by 29
Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?
Ward, N. C., Kostner, K., SULLIVAN, D. R., Nestel, P. J., & Watts, G. F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122073 · Cited by 32
“This method also expresses Lp(a) concentration in nanomoles per litre [92,93].”
MethodSingh, S. S., Rashid, M., Lieverse, A. G., Kronenberg, F., Lamina, C., Mulder, M. T., de Rijke, Y. B., Sijbrands, E. J. G., & van Hoek, M. (2020) · Diabetologia · doi:10.1007/s00125-020-05120-9 · Cited by 28
“Marcovina et al [48] showed that these biases among methods of Lp(a) plasma measurement can substantially affect the outcomes.”
BackgroundRoth, C., Krychtiuk, K. A., Gangl, C., Schrutka, L., Distelmaier, K., Wojta, J., Hengstenberg, C., Berger, R., & Speidl, W. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227054 · Cited by 29
“It has been shown that Lp(a) can decline by 7% within a storage time of 2 years [21], which could have been a confounder in previous studies with long-time storage of plasma samples before analysis.”
BackgroundKarwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N. J., Witztum, J. L., Marcovina, S. M., & Tsimikas, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.036 · Cited by 27
Self-citationElevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review
Masson, W. M., Lobo, M., Barbagelata, L., Molinero, G., Bluro, I. M., & Nogueira, J. P. (2022) · Vascular Medicine · doi:10.1177/1358863x221091320 · Cited by 31
Metadata
- Authors
- Marcovina, S. M., & Albers, J. J.
- Affiliations
- University of Washington (US)
- Corresponding author
- Marcovina, Santica M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 57
- Issue
- 4
- Pages
- 526-537
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4808779
- OpenAlex
- W2313206757
- Cited by
- 338
- References
- 49
- Citations by year
- 2026: 44 · 2025: 36 · 2024: 37 · 2023: 45 · 2022: 31 · 2021: 29 · 2020: 35 · 2019: 28 · 2018: 16 · 2017: 26 · 2016: 11
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1631 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), apolipoprotein(a), apo(a) isoforms, immunoassay standardization, antibody specificity, size heterogeneity, assay validation, measurement harmonization, coronary artery disease risk, clinical interpretation
- MeSH terms
- Apolipoproteins A, Cardiovascular Diseases, Data Interpretation, Statistical, Humans, Immunoassay, Reference Standards, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.